Novartis

Novartis receives Health Canada approval for VANRAFIAᵀᴹ (atrasentan tablet) for proteinuria reduction in adults with primary immunoglobulin A nephropathy (IgAN)

Montreal, July 13, 2026 – Novartis Pharmaceuticals Canada Inc. (“Novartis Canada”) announced today that Health Canada has granted approval for VANRAFIA TM (atrasentan tablets) for proteinuria ...
Novartis

Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer pati…

Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact ...
Novartis

Tatjana Dreyer ist Head Communications & Patient Advocacy bei Novartis Deutschland

Nürnberg, 06. Juli 2026 – Tatjana Dreyer hat zum 1. Juli 2026 die Position als Head Communications & Patient Advocacy bei Novartis Deutschland übernommen. In dieser Funktion gehört sie dem Country ...
Novartis

Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

Basel, July 2, 2026 – Novartis today announced that the European Commission (EC) has approved Itvisma ® (onasemnogene ...
Novartis

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

About Novartis Immunology At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune diseases. Building on our legacy of ...
Novartis

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

Novartis’ commitment to kidney diseases Building on a legacy of more than 40 years that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, ...
Novartis

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US ...
Novartis

Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)

studies were published in Nature Medicine. Following the CHMP’s recommendation for approval, the European Commission (EC) is expected to issue a final decision within approximately two months. About ...
Novartis

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presented Long-term Cosentyx® data build on extensive body of evidence ...
Novartis

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818, ...
Novartis

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early ...